New insights in sublingual immunotherapy

Current Allergy and Asthma Reports

Volumn 6, Issue 5, 2006, Pages 407-412

  Passalacqua, Giovanni ^a   Guerra, Laura ^b   Compalati, Enrico ^b   Fumagalli, Federica ^b   Cirillo, Arianna ^b   Canonica, Giorgio Walter ^b  

^a DIMI   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; HOUSE DUST ALLERGEN; LATEX; PLACEBO; RAGWEED ANTIGEN;

ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ALLERGIC RHINITIS; ASTHMA; CLINICAL TRIAL; DESENSITIZATION; DIARRHEA; DOSE RESPONSE; FOOD ALLERGY; GASTROINTESTINAL SYMPTOM; GRASS; HUMAN; IMMUNOTHERAPY; MOUTH INFLAMMATION; NAUSEA; PARIETARIA; PATIENT COMPLIANCE; PRURITUS; REVIEW; RHINOCONJUNCTIVITIS; SAFETY; STOMACH PAIN;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS; RESPIRATORY HYPERSENSITIVITY;

EID: 33748432970     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-996-0014-7     Document Type: Review

References (68)

1. Bernstein DI, Wanner M, Borish L, Liss GM: Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004, 113:1129-1136.
2. Aaronson DW, Gandhi TK: Incorrect allergy injections: allergists' experiences and recommendations for prevention. J Allergy Clin Immunol 2004, 113:1117-1121.
3. Malling HJ, Weeke B: EAACI immunotherapy position paper. Allergy 1993, 48:9-35.
4. Scadding K, Brostoff J: Low-dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin Allergy 1986, 16:483-491.
5. Bousquet J, Lockey R, Malling HJ: World Health Organization Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Allergy 1998, 53:1-33.
6. Bousquet J, Van Cauwenberge P: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001, 108:S146-S150.
7. Passalacqua G, Villa G, Altrinetti V, et al.: Sublingual swallow or spit? Allergy 2001, 56:578-582.
8. Passalacqua G, Guerra L, Pasquali M, Canonica GW: Efficacy and safety of sublingual immunotherapy. Ann Allergy Asthma Immunol 2004, 93:3-12.
9. Canonica GW, Passalacqua G: Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003, 111:437-448.
10. Ariano R. Spadolini I, Panzani RC: Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double-blind study. Allergol Immunopathol (Madr) 2001, 29:238-244.
11. Bahcecilier NN, Isik U, Barlan IB, Basaran N: Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001, 32:49-55.
12. Voltolini S, Modena P, Minale P, et al.: Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo controlled study with a biologically standardized extract of tree pollen (alder, birch, and hazel) administered by a rush schedule. Allergol Immunopathol 2001, 29:103-110.
13. Lima MT, Wilson D, Pitkin L, et al.: Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002, 32:507-514.
14. Mortemousque B, Bertel F, De Casamayor J, et al.: House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 2003, 33:464-469.
15. Andrè C, Perrin-Fayolle M, Grosclaude M, et al.: A double blind placebo controlled evaluation of SLIT with a standardized ragweed extract in patients with seasonal rhinitis. Int Arch Allergy Immunol 2003, 131:111-118.
16. Ippoliti F, De Sanctis W, Volterrani A, et al.: Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003, 14:216-221.
17. Pajno G, Vita D, Caminiti D, et al.: Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy 2003, 33:1641-1647.
18. Wuthrich B, Bucher C, Jorg W, et al.: Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen. J Investig Allergol Clin Immunol 2003, 13:145-148.
19. Tonnel AB, Scherpereel A, Douay B, et al.: Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004, 59:491-497.
20. Smith H, White P, Annila I, et al.: Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol 2004, 114:831-837.
21. Rolinck-Werninghaus C, Wolf H, Liebke C, et al.: A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy 2004, 59:1285-1293.
22. Bowen T, Greenbaum J, Charbonneau Y, et al.: Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol 2004, 93:425-430.
23. Bufe A, Ziegler-Kirbach E, Stoeckmann E et al.: Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004, 59:498-504.
24. Dahl R, Stender H, Rak S: Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006, 61:185-190.
25. Passalacqua G, Pasquali M, Ariano R, et al.: Randomized double-blind controlled study with sublingual carbamylated allergoid in mild rhinitis due to mites. Allergy 2006, 61:849-854.
26. Niu CK, Chen WY, Huang JL, et al.: Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 2006, Epub ahead of print.
27. Durham SR, Yang WH, Pedersen MR, et al.: Sublingual immunotherapy with once-daily grass-allergen tablets: a randomised controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117:802-809.
28. Khinchi MS, Poulsen LK, Carat F, et al.: Clinical efficacy of sublingual and subcutaneous birch pollen allergen specific immunotherapy. A randomized placebo controlled, double blind, double dummy study. Allergy 2004, 59:33-44.
29. Wilson DR, Torres L, Durham SR: Sublingual immunotherapy for allergic rhinitis. Allergy 2005, 60:3-8.
30. Penagos M, Tarantini E, Compalati E, et al.: Efficacy of sublingual immunotherapy for rhinitis. Meta analysis in pediatric patients. Ann Allergy Asthma Immunol 2006, In press.
31. Bousquet J, Scheinmann P, Guinnepain MT et al.: Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999, 54:249-260.
32. Marogna M, Spadolini I, Massolo A, et al.: Clinical functional and immunological effects of sublingual immunotherapy in birch allergy. J Allergy Clin Immunol 2005, 115:1184-1188.
33. Pajno G, Passalacqua G, Vita D, et al.: Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. Allergy 2004, 59:883-887.
34. Patriarca G, Nucera E, Pollastrini E, et al.: Sublingual desensitization: a new approach to latex allergy problem. Anesth Analg 2002, 95:956-960.
35. Sastre J, Fernandez-Nieto M, Rico P, et al.: Specific immunotherapy with a standardized latex extract in allergic workers: a double-blind, placebo-controlled study. J Allergy Clin Immunol 2003, 111:985-994.
36. Enrique E, Pineda F, Malek T, et al.: Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 2005, 116:1073-1079.
37. Kleine-Tebbe J, Ribel M, Herold DA: Safety of a SQ-standardised grass allergen tablet or sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 2006, 61:181-184.
38. Di Rienzo V, Pagani A, Parmiani S, et al.: Post-marketing surveillance study on the safety of sublingual immunotherapy in children Allergy 1999, 54:1110-1113.
39. Lombardi C, Gargioni S, Melchiorre A, et al.: Safety of sublingual immunotherapy in adults: a post marketing surveillance study. Allergy 2001, 56:889-892.
40. Pajno GB, Peroni DG, Vita D, et al.: Safety of sublingual immunotherapy in children with asthma. Paediatr Drugs 2003, 5:777-781.
41. Agostinis F, Tellarini L, Falagiani P, et al.: Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy 2005, 60:133.
42. Fiocchi A, Paino G, La Grutta S, et al.: Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol 2005, 95:254-258.
43. Di Rienzo V, Minelli M, Musarra A, et al.: Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005, 35:560-564.
44. Gidaro GB, Frati F, Sensi L, et al.: The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005, 35:565-571.
45. Pajno G, Barberio G, De Luca F, et al.: Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001, 31:1392-1397.
46. Purello D'Ambrosio F, Gangemi S, Merendino RA, et al.: Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001, 31:1295-1302.
47. Durham SR, Walker SM, Varga EM, et al.: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341:468-475.
48. Moller C, Dreborg S, Ferdousi HA, et al.: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002, 109:251-256.
49. Di Rienzo V, Marcucci F, Puccinelli P, et al.: Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a ten year prospective study. Clin Exp Allergy 2003, 33:206-210.
50. Marogna M, Spadolini I, Massolo A, et al.: Randomized controlled open study of SLIT for respiratory allergy in real life: clinical efficacy and more. Allergy 2004, 59:1205-1210.
51. Novembre E, Galli E, Landi F, et al.: Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004, 114:851-857.
52. Lombardi C, Gani F, Landi M, et al.: Quantitative assessment of the adherence to sublingual immunotherapy. J Allergy Clin Immunol 2004, 113:1219-1220.
53. Passalacqua G, Musarra A, Pecora S, et al.: Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year). J Allergy Clin Immunol 2006, 117:946-948.
54. Pajno GB, Vita D, Caminiti L, et al.: Children's compliance with allergen immunotherapy according to administration routes. J Allergy Clin Immunol 2005, 116:1380-1381.
55. Rossi R, Monasterolo RE: A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol 2005, 18:277-285.
56. Tripodi S, Di Rienzo Businco A, Benincori N, et al.: Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. Int Arch Allergy Immunol 2005, 139:149-152.
57. Guerra L, Compalati E, Rogkakou A, et al.: Randomized open comparison of the safety of SLIT in a no updosing and traditional updosing schedule in patients with parietaria allergy. Allergol Immunopathol 2006, 34:82-83.
58. Passalacqua G, Albano M, Fregonese L, et al.: Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998, 351:629-632.
59. Passalacqua G, Albano M, Fregonese L, et al.: Clinical and immunological effects of a rush sublingual immunotherapy to parietaria: a double blind placebo controlled study. J Allergy Clin Immunol 1999, 104:964-968.
60. Bahceciler NN, Arikan C, Taylor A, et al.: Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005, 136:287-294.
61. Marcucci F, Sensi L, Di Cara G, et al.: Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sublingual immunotherapy. Pediatr Allergy Immunol 2005, 16:519-526.
62. Rolinck-Werninghaus C, Kopp M, Liebke C, et al.: Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol 2005, 136:134-141.
63. Cosmi L, Santarlasci V, Angeli R, et al.: Sublingual immunotherapy with Dermatophagoides monomeric allergoid downregulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production. Clin Exp Allergy 2006, 36:261-272.
64. Ciprandi G, Fenoglio D, Cirillo I, et al.: Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 2005, 95:38-44.
65. Moingeon P, Batard T, Fadel R, et al.: Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006, 61:151-165.
66. Bagnasco M, Passalacqua G, Villa G: Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy 2001, 31:54-60.
67. Bagnasco M, Altrinetti V, Pesce G, et al.: Pharmacokinetics of radiolabelled Der p 2 allergen and monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol 2005, 138:197-202.
68. Bieber T: Allergen-specific sublingual immunotherapy: less mystic, more scientific. Allergy 2006, 61:149-150.